|
54
|
130
|
6epuA |
The atad2 bromodomain in complex with compound 2 |
|
37
|
102
|
6bqaA |
Brd9 bromodomain in complex with 3-(6-(but-3-en-1-yl)-7-oxo-6,7-dihydro-1h-pyrrolo[2,3-c]pyridin-4-yl)-n,n-dimethylbenzamide |
|
55
|
233
|
6albA |
Crebbp bromodomain in complex with cpd 30 (1-(3-(3-(1-methyl-1h-pyrazol-4-yl)isoquinolin-8-yl)-1-(tetrahydro-2h-pyran-4-yl)-1,4,6,7-tetrahydro-5h-pyrazolo[4,3-c]pyridin-5-yl)ethan-1-one) |
|
42
|
126
|
5owmA |
Crystal structure of human brd4(1) bromodomain in complex with ut48 |
|
42
|
126
|
5yovA |
Crystal structure of brd4-bd1 bound with hjp126 |
|
39
|
123
|
5youA |
Crystal structure of brd4-bd1 bound with hjp64 |
|
42
|
124
|
6q3yA |
Crystal structure of the first bromodomain of human brd4 in complex with the inhibitor 16i |
|
42
|
126
|
5ovbA |
Crystal structure of human brd4(1) bromodomain in complex with dr46 |
|
44
|
126
|
5yqxA |
Crystal structure analysis of the brd4 |
|
41
|
124
|
6q3zA |
Crystal structure of the first bromodomain of human brd4 in complex with the inhibitor 16k |
|
44
|
116
|
6nezA |
Trypanosoma brucei - bdf5, tb427tmp.01.5000 a, solved with pf-cbp1 |
|
42
|
109
|
6moaA |
C-terminal bromodomain of human brd2 in complex with 4-(2-cyclopropyl-7-(6-methylquinolin-5-yl)-1h-benzo[d]imidazol-5-yl)-3,5-dimethylisoxazole inhibitor |
|
42
|
114
|
6mo8A |
N-terminal bromodomain of human brd2 in complex with 4,4'-(quinoline-5,7-diyl)bis(3,5-dimethylisoxazole) inhibitor |
|
41
|
114
|
6mo7A |
N-terminal bromodomain of human brd2 with n-((4-(3-(n-cyclopentylsulfamoyl)-4-methylphenyl)-3-methylisoxazol-5-yl)methyl)acetamide inhibitor |
|
41
|
114
|
6mo9A |
N-terminal bromodomain of human brd2 in complex with n-cyclopentyl-7-(3,5-dimethylisoxazol-4-yl)quinoline-5-sulfonamide inhibitor |
|
51
|
130
|
6hi6A |
The atad2 bromodomain in complex with compound 9 |
|
53
|
130
|
6hi4A |
The atad2 bromodomain in complex with compound 7 |
|
52
|
130
|
6hi7A |
The atad2 bromodomain in complex with compound 10 |
|
52
|
130
|
6hicA |
The atad2 bromodomain in complex with compound 15 |
|
43
|
112
|
6hm0A |
Crystal structure of human brd9 bromodomain in complex with a protac |
|
52
|
130
|
6hieA |
The atad2 bromodomain in complex with compound 17 |
|
53
|
130
|
6hiaA |
The atad2 bromodomain in complex with compound 13 |
|
51
|
130
|
6hi5A |
The atad2 bromodomain in complex with compound 8 |
|
51
|
130
|
6hibA |
The atad2 bromodomain in complex with compound 14 |
|
52
|
130
|
6hidA |
The atad2 bromodomain in complex with compound 16 |
|
45
|
129
|
6hi3A |
The atad2 bromodomain in complex with compound 4 |
|
52
|
131
|
6cpsA |
Crystal structure of the bromodomain of human atad2 with a disulfide bridge |
|
37
|
114
|
6fqtA |
Crystal structure of crebbp bromodomain complexd with dr46 |
|
40
|
113
|
6dmkA |
A multiconformer ligand model of an isoxazolyl-benzimidazole ligand bound to the bromodomain of human crebbp |
|
43
|
125
|
6cj2A |
Crystal structure of the first bromodomain of human brd4 in complex with the inhibitor jwg056 |
|
42
|
127
|
6dmlA |
A multiconformer ligand model of 3,5 dimethylisoxaxole bound to the bromodomain of human brd4 |
|
41
|
127
|
6dmjA |
A multiconformer ligand model of inhibitor 53w bound to creb binding protein bromodomain |
|
43
|
113
|
6ffgA |
Human brd2 c-terminal bromodomain with (s)-1-(2-cyclopropyl-4-(2-(hydroxymethyl)benzyl)-6-(1,2,3,6-tetrahydropyridin-4-yl)-3,4-dihydroquinoxalin-1(2h)-yl)ethanone |
|
52
|
129
|
6bqdA |
Taf1-bd2 bromodomain in complex with (e)-3-(6-(but-2-en-1-yl)-7-oxo-6,7-dihydro-1h-pyrrolo[2,3-c]pyridin-4-yl)-n,n-dimethylbenzamide |
|
39
|
113
|
6ffdA |
Human brd4 c-terminal bromodomain with 1-(4-(3-methylbenzyl)-3,4-dihydroquinoxalin-1(2h)-yl)ethanone |
|
44
|
113
|
6fffA |
Human brd2 c-terminal bromodomain with (s)-5-(1-acetyl-2-cyclopropyl-4-(2-(hydroxymethyl)benzyl)-1,2,3,4-tetrahydroquinoxalin-6-yl)pyrimidine-2-carboxamide |
|
42
|
127
|
6afrA |
Crystal structure of the first bromodomain of human brd4 in complex with 5-((4-fluoro-1h-imidazol-1-yl)methyl)quinolin-8-ol |
|
43
|
125
|
6cd5A |
Crystal structure of the first bromodomain of human brd4 in complex with the inhibitor xmd17-26 |
|
45
|
133
|
5z1sA |
Crystal structure analysis of the brd4(1) |
|
41
|
127
|
5z8gA |
Brd4 bromodomain 1 with an inhibitor |
|
39
|
124
|
5z5uA |
The first bromodomain of brd4 with compound bdf-2254 |
|
40
|
127
|
5z90A |
Brd4 bromodomain 1 with an inhibitor |
|
44
|
134
|
5z1rA |
Crystal structure analysis of the brd4 |
|
37
|
127
|
5z8rA |
Brd4 bromodomain 1 with an inhibitor |
|
41
|
127
|
5z8zA |
Brd4 bromodomain 1 with an inhibitor |
|
41
|
124
|
5z5vA |
The first bromodomain of brd4 with compound bdf-1253 |
|
44
|
135
|
5z1tA |
Crystal structure analysis of the brd4(1) |
|
41
|
123
|
5z9kA |
Brd4 bromodomain 1 with an inhibitor |
|
43
|
124
|
5z5tA |
The first bromodomain of brd4 with compound bdf-2141 |
|
38
|
108
|
6j3pA |
Crystal structure of the human gcn5 bromodomain in complex with compound (r,r)-36n |
